WO1999017787A3 - Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response - Google Patents

Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response Download PDF

Info

Publication number
WO1999017787A3
WO1999017787A3 PCT/IB1998/001676 IB9801676W WO9917787A3 WO 1999017787 A3 WO1999017787 A3 WO 1999017787A3 IB 9801676 W IB9801676 W IB 9801676W WO 9917787 A3 WO9917787 A3 WO 9917787A3
Authority
WO
WIPO (PCT)
Prior art keywords
chlorite solution
stabilized chlorite
antigen
immune response
inhibiting
Prior art date
Application number
PCT/IB1998/001676
Other languages
French (fr)
Other versions
WO1999017787A2 (en
Inventor
Edgar G Engleman
Frederich W Kuhne
Michael Mcgrath
Original Assignee
Oxo Chemie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US6095397P priority Critical
Priority to US60/060,953 priority
Application filed by Oxo Chemie Ag filed Critical Oxo Chemie Ag
Publication of WO1999017787A2 publication Critical patent/WO1999017787A2/en
Publication of WO1999017787A3 publication Critical patent/WO1999017787A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Methods of using a stabilized chlorite solution to inhibit antigen-specific immune responses are disclosed. The stabilized chlorite solution, when administered to a mammal in need thereof, can prevent the presentation of antigens by antigen presenting cells. The stabilized chlorite solution therefore is useful in treating, inter alia, auto-immune diseases, treating diseases caused by an inappropriate immune response, treating lymphoproliferative disease and in inhibiting rejection in transplant patients.
PCT/IB1998/001676 1997-10-06 1998-10-06 Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response WO1999017787A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US6095397P true 1997-10-06 1997-10-06
US60/060,953 1997-10-06

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DE69821506T DE69821506T2 (en) 1997-10-06 1998-10-06 USE OF A CHEMICALLY STABILIZED CHLORITE SOLUTION FOR INHIBITING THE ANTI-SPECIFIC IMMUNE RESPONSE
JP2000514658A JP4369615B2 (en) 1997-10-06 1998-10-06 Use of chemically stabilized chlorite solutions to suppress antigen-specific immune responses
CA002306273A CA2306273A1 (en) 1997-10-06 1998-10-06 Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response
DK98946681T DK1021196T3 (en) 1997-10-06 1998-10-06 Use of a chemically stabilized chlorite solution to inhibit an antigen-specific immune response
AT98946681T AT258799T (en) 1997-10-06 1998-10-06 Use of a chemically stabilized chlorite solution for inhibiting the anti-specific immune response
AU93642/98A AU754928B2 (en) 1997-10-06 1998-10-06 Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response
EP98946681A EP1021196B1 (en) 1997-10-06 1998-10-06 Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response

Publications (2)

Publication Number Publication Date
WO1999017787A2 WO1999017787A2 (en) 1999-04-15
WO1999017787A3 true WO1999017787A3 (en) 1999-06-17

Family

ID=22032774

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1998/001676 WO1999017787A2 (en) 1997-10-06 1998-10-06 Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response

Country Status (12)

Country Link
US (4) US20050129784A1 (en)
EP (1) EP1021196B1 (en)
JP (1) JP4369615B2 (en)
CN (1) CN1152691C (en)
AT (1) AT258799T (en)
AU (1) AU754928B2 (en)
CA (1) CA2306273A1 (en)
DE (1) DE69821506T2 (en)
DK (1) DK1021196T3 (en)
ES (1) ES2217582T3 (en)
PT (1) PT1021196E (en)
WO (1) WO1999017787A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1378456A (en) * 1999-08-18 2002-11-06 奥克索化学有限公司 Chemically-stabilized chlorite solutions for treating cancer and other diseases
AU2011205095B2 (en) * 2004-02-03 2014-07-03 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
CA2919344C (en) 2005-12-22 2017-02-28 Neuraltus Pharmaceuticals, Inc. Chlorite formulations, and methods of preparation and use thereof
US8252343B2 (en) * 2007-06-01 2012-08-28 Nuvo Research Ag Use of WF10 for treating allergic asthma, allergic rhinitis and atopic dermatitis
CA2770023A1 (en) 2009-08-06 2011-02-10 Neuraltus Pharmaceuticals, Inc. Treatment of macrophage-related disorders
US9266957B2 (en) 2009-11-10 2016-02-23 Mayo Foundation For Medical Education And Research Methods and materials for treating renal cell carcinoma and glioblastoma multiforme
JP2015502400A (en) 2011-12-22 2015-01-22 ヌーボ リサーチ ゲイエムベーハー Liposomal chlorite or chlorate composition
EP2804612A4 (en) * 2012-01-19 2015-09-02 Ibt Pharma Inc Therapeutic uses of tetrachlorodecaoxygen (tcdo)
US9970936B2 (en) 2012-11-13 2018-05-15 Mayo Foundation For Medical Education And Research Methods and materials for assessing immune system profiles
US10094835B2 (en) 2013-05-09 2018-10-09 Mayo Foundation For Medical Education And Research Treating patients based on immune subtypes
WO2017029648A1 (en) 2015-08-20 2017-02-23 Oxo Chemie (Thailand) Co., Ltd Use of chlorite to treat red blood cell diseases and indications mediated thereby

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0200157A2 (en) * 1985-05-02 1986-11-05 OXO Chemie GmbH Use of an aqueous stabilized chlorite matrix solution for the manufacture of a medicament for the treatment of infectious conditions by intravenous administration
US4851222A (en) * 1988-01-27 1989-07-25 Oxo Chemie Gmbh Method of promoting regeneration of bone marrow
EP0561145A1 (en) * 1992-03-19 1993-09-22 Oxo Chemie Ag Use of a chemicallly stabilized chlorite matrix for the manufacture of medicaments for the treatment of HIV infections
WO1996028173A1 (en) * 1994-12-23 1996-09-19 Bioxy Incorporated Biocidal compositions containing halides and oxyhalides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4574084A (en) * 1983-02-25 1986-03-04 Peter Berger Process for the preparation of a modified aqueous chlorite solution, the solution prepared by this process and the use thereof
DE3515745A1 (en) * 1985-05-02 1986-11-06 Oxo Chemie Gmbh AQUEOUS CHLORITE MATRIX SOLUTION
US4956184A (en) * 1988-05-06 1990-09-11 Alcide Corporation Topical treatment of genital herpes lesions
US5877222A (en) * 1996-07-19 1999-03-02 The Regents Of The University Of California Method for treating aids-associated dementia
US8252343B2 (en) * 2007-06-01 2012-08-28 Nuvo Research Ag Use of WF10 for treating allergic asthma, allergic rhinitis and atopic dermatitis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0200157A2 (en) * 1985-05-02 1986-11-05 OXO Chemie GmbH Use of an aqueous stabilized chlorite matrix solution for the manufacture of a medicament for the treatment of infectious conditions by intravenous administration
US4851222A (en) * 1988-01-27 1989-07-25 Oxo Chemie Gmbh Method of promoting regeneration of bone marrow
EP0561145A1 (en) * 1992-03-19 1993-09-22 Oxo Chemie Ag Use of a chemicallly stabilized chlorite matrix for the manufacture of medicaments for the treatment of HIV infections
WO1996028173A1 (en) * 1994-12-23 1996-09-19 Bioxy Incorporated Biocidal compositions containing halides and oxyhalides

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE AIDSLINE US NATIONAL LIBRARY OF MEDICINE (NLM),BETHESDA, MD, US; BUSCH HW ET AL: "Treatment of HIV-infected patients with advanced symptomatic disease with WF10 solution (TCDO).", XP002098534 *
DATABASE EMBASE ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; KEMPF S.R. ET AL: "Comparative study on the effects of chlorite oxygen reaction product TCDO (tetrachlorodecaoxygen) and sodium chlorite solution (NaClOinf 2) with equimolar chlorite content on bone marrow and peripheral blood of BDIX rats", XP002098535 *
DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH (DRUGS EXP. CLIN. RES.), 1993, 19/4 (165-174), Switzerland *
ELSTNER E.F.: "Oxygen radicals - Biochemical basis for their efficacy", KLINISCHE WOCHENSCHRIFT (KLIN. WOCHENSCHR.), 1991, 69/21-23 (949-956), Germany, XP002098533 *
INT CONF AIDS, AUG 7-12 1994, 10 (1) P204 (ABSTRACT NO. PB0245) *

Also Published As

Publication number Publication date
EP1021196B1 (en) 2004-02-04
EP1021196A2 (en) 2000-07-26
CN1152691C (en) 2004-06-09
US20110076344A1 (en) 2011-03-31
US20090004295A1 (en) 2009-01-01
DK1021196T3 (en) 2004-06-07
JP4369615B2 (en) 2009-11-25
DE69821506T2 (en) 2004-12-16
AT258799T (en) 2004-02-15
PT1021196E (en) 2004-06-30
CA2306273A1 (en) 1999-04-15
US20050129784A1 (en) 2005-06-16
JP2001518512A (en) 2001-10-16
WO1999017787A2 (en) 1999-04-15
AU754928B2 (en) 2002-11-28
CN1306433A (en) 2001-08-01
US20120141514A1 (en) 2012-06-07
ES2217582T3 (en) 2004-11-01
AU9364298A (en) 1999-04-27
DE69821506D1 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
Bloom et al. Selective primary health care: strategies for control of disease in the developing world. V. Leprosy
Vallejo et al. Antigen processing and presentation in teleost immune responses
WO1999017787A3 (en) Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response
NZ506651A (en) Il-12 enhancement of immune responses to t-independent antigens
CA2233042A1 (en) Specific binding members for human transforming growth factor beta; materials and methods
WO1996012794A3 (en) Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity
CA2149329A1 (en) Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
Lee et al. Cell-mediated immunity (CMI) to human wart virus and wart-associated tissue antigens.
CA2215203A1 (en) Vaccines for plague
WO2003045427A3 (en) Pharmaceutical composition for inducing an immune response in a human or animal
Rotman et al. IL‐12 eliminates the Th‐2 dependent protective immune response of mice to larval Strongyloides stercoralis
Zuckerman et al. Immunologic specificity of transfer factor
EP0863913A4 (en) A method to increase the density of antigen on antigen presenting cells
CA2078235A1 (en) Idiotypic vaccination against b cell lymphoma
CA2295604A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation
CA2169297A1 (en) Protein- or peptide-cochleate vaccines and methods of immunizing using the same
Phanuphak et al. Tolerance and contact sensitivity to DNFB in mice. II. Specific in vitro stimulation with a hapten, 2, 4-Dinitrobenzene sulfonic acid (DNB· SO3Na)
Safai et al. Immunodermatology
Burns et al. Immunology and infectious disease
IL92629D0 (en) Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases
IE881282L (en) Monoclonal antibodies to specific antigenic regions of the¹human immunodeficiency virus and methods for use.
Lanzavecchia Clonal sketches of the immune response.
Dennert et al. Induction and properties of cytotoxic T cells specific for hapten-coupled tumor cells
CA2157500A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t-cell activation and proliferation
Belehu et al. Immunopathological aspects of leishmaniasis

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98811885.8

Country of ref document: CN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN JP

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2306273

Country of ref document: CA

Ref document number: 2306273

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 93642/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998946681

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998946681

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 93642/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1998946681

Country of ref document: EP